Merck Partners with Calla Lily to Advance Callavid as Shares Trade at 16x Earnings
Merck and Calla Lily have entered a collaboration to advance the Callavid immunotherapy platform through preclinical stages into Phase I trials. Merck currently trades at 16x trailing earnings, representing an 18.7% undervaluation relative to peers, supported by a robust late-stage drug pipeline offsetting patent-cliff pressures.
1. Partnership with Calla Lily
Merck has teamed up with Calla Lily to co-develop the Callavid immunotherapy platform, targeting novel cancer antigens. The collaboration will progress preclinical assets into Phase I clinical trials, with structured research funding, undisclosed upfront fees and potential milestones driving near-term R&D investment.
2. Valuation and Pipeline Outlook
Shares trade at a 16x trailing price-earnings multiple, implying an 18.7% undervaluation versus peer group averages. This discount is underpinned by a diversified late-stage drug portfolio—spanning oncology, vaccines and antiviral candidates—that helps mitigate looming patent expirations and supports long-term revenue growth projections.